Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors : a Danish population-based cohort study
(2020) In Breast Cancer Research and Treatment 183(1). p.153-160- Abstract
Purpose: To examine the association between statin use and risk of breast cancer recurrence in a national Danish cohort of postmenopausal breast cancer patients receiving aromatase inhibitors (AI) in the adjuvant setting. Patients and methods: We enrolled all postmenopausal patients diagnosed with stage I–III estrogen receptor positive breast cancer during the years 2007–2017, assigned adjuvant AI treatment, and registered in both the Danish Breast Cancer Group database and the Danish Cancer Registry. We ascertained incident statin exposure (≥ 1 prescription post-diagnosis) from the Danish National Prescription Registry and modeled statins as a time-varying exposure lagged by 6 months. Follow-up began 7 months after diagnosis and... (More)
Purpose: To examine the association between statin use and risk of breast cancer recurrence in a national Danish cohort of postmenopausal breast cancer patients receiving aromatase inhibitors (AI) in the adjuvant setting. Patients and methods: We enrolled all postmenopausal patients diagnosed with stage I–III estrogen receptor positive breast cancer during the years 2007–2017, assigned adjuvant AI treatment, and registered in both the Danish Breast Cancer Group database and the Danish Cancer Registry. We ascertained incident statin exposure (≥ 1 prescription post-diagnosis) from the Danish National Prescription Registry and modeled statins as a time-varying exposure lagged by 6 months. Follow-up began 7 months after diagnosis and continued to the first event of recurrence, death, emigration, 5 years elapsed, or 25th September 2018. We estimated incidence rates of recurrence at 5 years and used Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI), comparing statin exposure with non-exposure. Results: We enrolled 14,773 eligible patients. During the 5 years of follow-up, there were 32 recurrences in 3163 person-years of follow-up among statin-exposed patients, and 612 recurrences in 45,655 person-years among unexposed patients (incidence rate per 1000 person-years: 10.12 [95% CI 6.92–14.28] and 13.40 [95% CI 12.36–14.51], respectively). In multivariable models, any statin exposure was associated with a reduced rate of 5-year breast cancer recurrence (adjusted HR 0.72 [95% CI 0.50–1.04]). Considering only lipophilic statins as exposure the results were similar (adjusted HR 0.70 [95% CI 0.48–1.02]). Conclusions: Statin use was associated with a reduced risk of breast cancer recurrence among postmenopausal patients diagnosed with early stage breast cancer who received adjuvant AI therapy.
(Less)
- author
- Harborg, Sixten ; Heide-Jørgensen, Uffe ; Ahern, Thomas P. ; Ewertz, Marianne ; Cronin-Fenton, Deirdre and Borgquist, Signe LU
- organization
- publishing date
- 2020-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Aromatase inhibitors, Breast cancer, Cohort study, Endocrine therapy, Statins
- in
- Breast Cancer Research and Treatment
- volume
- 183
- issue
- 1
- pages
- 8 pages
- publisher
- Springer
- external identifiers
-
- pmid:32572715
- scopus:85086771388
- ISSN
- 0167-6806
- DOI
- 10.1007/s10549-020-05749-5
- language
- English
- LU publication?
- yes
- id
- 9e77a6db-e828-4baa-b597-73ed7341a6e0
- date added to LUP
- 2020-07-13 14:04:16
- date last changed
- 2024-04-17 12:41:42
@article{9e77a6db-e828-4baa-b597-73ed7341a6e0,
abstract = {{<p>Purpose: To examine the association between statin use and risk of breast cancer recurrence in a national Danish cohort of postmenopausal breast cancer patients receiving aromatase inhibitors (AI) in the adjuvant setting. Patients and methods: We enrolled all postmenopausal patients diagnosed with stage I–III estrogen receptor positive breast cancer during the years 2007–2017, assigned adjuvant AI treatment, and registered in both the Danish Breast Cancer Group database and the Danish Cancer Registry. We ascertained incident statin exposure (≥ 1 prescription post-diagnosis) from the Danish National Prescription Registry and modeled statins as a time-varying exposure lagged by 6 months. Follow-up began 7 months after diagnosis and continued to the first event of recurrence, death, emigration, 5 years elapsed, or 25th September 2018. We estimated incidence rates of recurrence at 5 years and used Cox regression models to compute crude and adjusted hazard ratios (HRs) with 95% confidence intervals (95% CI), comparing statin exposure with non-exposure. Results: We enrolled 14,773 eligible patients. During the 5 years of follow-up, there were 32 recurrences in 3163 person-years of follow-up among statin-exposed patients, and 612 recurrences in 45,655 person-years among unexposed patients (incidence rate per 1000 person-years: 10.12 [95% CI 6.92–14.28] and 13.40 [95% CI 12.36–14.51], respectively). In multivariable models, any statin exposure was associated with a reduced rate of 5-year breast cancer recurrence (adjusted HR 0.72 [95% CI 0.50–1.04]). Considering only lipophilic statins as exposure the results were similar (adjusted HR 0.70 [95% CI 0.48–1.02]). Conclusions: Statin use was associated with a reduced risk of breast cancer recurrence among postmenopausal patients diagnosed with early stage breast cancer who received adjuvant AI therapy.</p>}},
author = {{Harborg, Sixten and Heide-Jørgensen, Uffe and Ahern, Thomas P. and Ewertz, Marianne and Cronin-Fenton, Deirdre and Borgquist, Signe}},
issn = {{0167-6806}},
keywords = {{Aromatase inhibitors; Breast cancer; Cohort study; Endocrine therapy; Statins}},
language = {{eng}},
number = {{1}},
pages = {{153--160}},
publisher = {{Springer}},
series = {{Breast Cancer Research and Treatment}},
title = {{Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors : a Danish population-based cohort study}},
url = {{http://dx.doi.org/10.1007/s10549-020-05749-5}},
doi = {{10.1007/s10549-020-05749-5}},
volume = {{183}},
year = {{2020}},
}